The human body produces T cells to recognize and fight disease. Each T cell has a unique T cell receptor (or TCR) on its surface that surveils small fragments of proteins presented by other cells. Upon detecting evidence of cancer or infection, a subset of T cells binds the diseased cells and orchestrates their elimination. When tumors and infections cannot be eradicated naturally, researchers employ immunotherapies to boost the immune system’s effectiveness.
By inserting genes encoding a tumor-specific TCR into a patient’s T cells, researchers can engineer a large population of T cells to target tumor cells. This approach, called TCR gene therapy, has yielded clinical successes where conventional cancer treatments have failed. However, TCR gene therapy is not without risk. The introduced receptor can become tangled with the resident receptor in each engineered T cell, causing some of these cells to attack healthy cells. A new technique developed by Caltech researchers prevents this from happening, increasing the safety of TCR gene therapy.
Click here to Read the full article: Genetically engineering disease-fighting cells
Share this entry
- Dr. Deepika Jain is Named to the American Health Council’s Physician Board August 18, 2017
- The American Health Council Elects Dr. Luis E. Raez to Board of Physicians August 17, 2017
- AHC Highlights Dr. Leslie Kerzner’s Medical Research August 16, 2017
- Dr. Judith K. Glann, DNP/MSN/ACNP-BC/CCRN, is appointed to the American Health Council’s Nursing Board August 16, 2017
- American Health Council Names William Dillon, M.D. to Education Board August 16, 2017
- AHC Discusses Informed-Consent Legislation August 15, 2017